Suppression of colon inflammation by CD80 blockade: Evaluation in two murine models of inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 14, Issue 4, 2008, Pages 458-470

  Eri, Rajaraman ^a,b   Kodumudi, Krithika N ^a   Summerlin, Don John ^a   Srinivasan, Mythily ^a,c  

^a INDIANA UNIVERSITY SCHOOL OF DENTISTRY   (United States)

^b MATER MEDICAL RESEARCH INSTITUTE   (Australia)

^c Department of Oral Pathology Medicine and Radiology ^*  (United States)

Author keywords

CD80 blockade; IBD; Murine model

Indexed keywords

B7 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; METHIONYLGLUTAMINYLPROLYLPROLYLGLYCYLCYSTEINE; PEPTIDE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; COMPETITIVE INHIBITION; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENTERITIS; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TH1 CELL;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD80; BINDING, COMPETITIVE; COLITIS; COLON; CYTOKINES; FEMALE; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, SCID; OLIGOPEPTIDES; T-LYMPHOCYTES; TRINITROBENZENESULFONIC ACID;

EID: 42449098038     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20344     Document Type: Article

References (55)

1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657.
2. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627-1640.
3. Elson CO, Cong Y. Understanding immune-microbial homeostasis in intestine. Immunol Res. 2002;26:87-94.
4. Monteleone I, Vavassori P, Biancone L, et al. Immunoregulation in the gut: success and failures in human disease. Gut. 2002;50(suppl 3):III60-64.
5. Simpson SJ, de Jong YP, Comiskey M, et al. Pathways of T cell pathology in models of chronic intestinal inflammation. Int Rev Immunol. 2000;19:1-37.
6. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495-549.
7. Jansson A, Barnes E, Klenerman P, et al. A theoretical framework for quantitative analysis of the molecular basis of costimulation. J Immunol. 2005;175:1575-1585.
8. Van Der Merwe PA, Davis SJ. Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol. 2003;21:659-684.
9. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233-258.
10. Rogler G, Hausmann M, Spottl T, et al. T-cell co-stimulatory molecules are upregulated on intestinal macrophages from inflammatory bowel disease mucosa. Eur J Gastroenterol Hepatol. 1999;11:1105-1111.
11. Rugtveit J, Bakka A, Brandtzaeg P. Differential distribution of B7.1 (CD80) and B7.2 (CD86) costimulatory molecules on mucosal macrophage subsets in human inflammatory bowel disease (IBD). Clin Exp Immunol. 1997;110:104-113.
12. Grose RH, Howarth GS, Xian CJ, et al. Expression of B7 costimulatory molecules by cells infiltrating the colon in experimental colitis induced by oral dextran sulfate sodium in the mouse. J Gastroenterol Hepatol. 2001;16:1228-1234.
13. Kay BK, Williamson MP, Sudol M. The importance of being proline: the interaction of proline-rich motifs in signaling proteins with their cognate domains. FASEB J. 2000;14:231-241.
14. Ostrov DA, Shi W, Schwartz JC, et al. Structure of murine CTLA-4 and its role in modulating T cell responsiveness. Science. 2000;290:816-819.
15. Stamper CC, Zhang Y, Tobin JF, et al. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature. 2001;410:608-611.
16. Srinivasan M, Lu D, Eri R, et al. CD80 binding polyproline helical peptide inhibits T cell activation. J Biol Chem. 2005;280:10149-10155.
17. Srinivasan M, Eri R, Zunt SL, et al. Suppression of immune responses in collagen-induced arthritis by a rationally designed CD80-binding peptide agent. Arthritis Rheum. 2007;56:498-508.
18. Liu Z, Geboes K, Hellings P, et al. B7 interactions with CD28 and CTLA-4 control tolerance or induction of mucosal inflammation in chronic experimental colitis. J Immunol. 2001;167:1830-1838.
19. Neurath M, Fuss I, Strober W. TNBS-colitis. Int Rev Immunol. 2000;19:51-62.
20. Gonzalez PV, Cragnolini AB, Schioth HB, et al. Interleukin-1 beta-induced anorexia is reversed by ghrelin. Peptides. 2006;27:3220-3225.
21. Okamoto S, Watanabe M, Yamazaki M, et al. A synthetic mimetic of CD4 is able to suppress disease in a rodent model of immune colitis. Eur J Immunol. 1999;29:355-366.
22. Satoh T, Aramini JM, Li S, et al. Bioactive peptide design based on protein surface epitopes. A cyclic heptapeptide mimics CD4 domain 1 CC loop and inhibits CD4 biological function. J Biol Chem. 1997;272:12175-12180.
23. Srinivasan M, Gienapp IE, Stuckman SS, et al. Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28. J Immunol. 2002;169:2180-2188.
24. Fukata M, Michelsen KS, Eri R, et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol. 2005;288:G1055-1065.
25. Chen M, Deng A, Crowson AN, et al. Assessment of T-cell clonality via T-cell receptor-gamma rearrangements in cutaneous T-cell-dominant infiltrates using polymerase chain reaction and single-stranded DNA conformational polymorphism assay. Appl Immunohistochem Mol Morphol. 2004;12:373-379.
26. Aharoni R, Kayhan B, Arnon R. Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis. Inflamm Bowel Dis. 2005;11:106-115.
27. Dohi T, Ejima C, Kato R, et al. Therapeutic potential of follistatin for colonic inflammation in mice. Gastroenterology. 2005;128:411-423.
28. Caminschi I, Lucas KM, O'Keeffe MA, et al. Molecular cloning of F4/80-like-receptor, a seven-span membrane protein expressed differentially by dendritic cell and monocyte-macrophage subpopulations. J Immunol. 2001;167:3570-3576.
29. Nooren IM, Thornton JM. Structural characterisation and functional significance of transient protein-protein interactions. J Mol Biol. 2003;325:991-1018.
30. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev. 2004;3:301-317.
31. Park SH, Shalongo W, Stellwagen E. The role of PU conformations in the calculation of peptide fractional helix content. Protein Sci. 1997;6:1694-1700.
32. Parrot I, Huang PC, Khosla C. Circular dichroism and nuclear magnetic resonance spectroscopic analysis of immunogenic gluten peptides and their analogs. J Biol Chem. 2002;277:45572-45578.
33. Bajorath J. Structural biology of T-cell costimulatory proteins: New insights, more surprises. J Mol Graph Model. 2001;19:619-623.
34. Kim G, Levin M, Schoenberger SP, et al. Paradoxical effect of reduced costimulation in T cell-mediated colitis. J Immunol. 2007;178:5563-5570.
35. te Velde AA, Verstege MI, Hommes DW. Critical appraisal of the current practice in murine TNBS-induced colitis. Inflamm Bowel Dis. 2006;12:995-999.
36. Kuchroo VK, Das MP, Brown JA, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 1995;80:707-718.
37. Perrin PJ, June CH, Maldonado JH, et al. Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J Immunol. 1999;163:1704-1710.
38. van Deventer SJ. Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut. 2002;50(Suppl 3):III47-53.
39. Srinivasan M, Roeske RW. Immunomodulatory peptides from IgSF proteins: a review. Curr Protein Pept Sci. 2005;6:185-196.
40. Kim G, Schoenberger SP, Sharpe A, et al. Synergistic costimulation by both B7 molecules regulates colitis pathogenesis. Ann N Y Acad Sci. 2006;1072:233-241.
41. Nakazawa A, Watanabe M, Kanai T, et al. Functional expression of costimulatory molecule CD86 on epithelial cells in the inflamed colonic mucosa. Gastroenterology. 1999;117:536-545.
42. Vincenti F, Luggen M. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu Rev Med. 2007;58:347-358.
43. Hurst SD, Cooper CJ, Sitterding SM, et al. The differentiated state of intestinal lamina propria CD4+ T cells results in altered cytokine production, activation threshold, and costimulatory requirements. J Immunol. 1999;163:5937-5945.
44. Taylor-Robinson AW, Smith EC. Modulation of experimental blood stage malaria through blockade of the B7/CD28 T-cell costimulatory pathway. Immunology. 1999;96:498-504.
45. Thompson CB. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell. 1995;81:979-982.
46. Webb LM, Feldmann M. Critical role of CD28/B7 costimulation in the development of human Th2 cytokine-producing cells. Blood. 1995;86:3479-3486.
47. Hara J, Ohtani H, Matsumoto T, et al. Expression of costimulatory molecules B7-1 and B7-2 in macrophages and granulomas of Crohn's disease: demonstration of cell-to-cell contact with T lymphocytes. Lab Invest. 1997;77:175-184.
48. Watanabe N, Ikuta K, Okazaki K, et al. Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice. Dig Dis Sci. 2003;48:408-414.
49. Iqbal N, Oliver JR, Wagner FH, et al. T helper 1 and T helper 2 cells are pathogenic in an antigen-specific model of colitis. J Exp Med. 2002;195:71-84.
50. May KF, Jr., Chang X, Zhang H, et al. B7-deficient autoreactive T cells are highly susceptible to suppression by CD4(+)CD25(+) regulatory T cells. J Immunol. 2007;178:1542-1552.
51. Delgado M, Leceta J, Gomariz RP, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J Immunol. 1999;163:3629-3635.
52. Grutz G. New insights into the molecular mechanism of interleukin-10-mediated immunosuppression. J Leukoc Biol. 2005;77:3-15.
53. Taylor A, Verhagen J, Blaser K, et al. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology. 2006;117:433-442.
54. Coenen JJ, Koenen HJ, van Rijssen E, et al. Tolerizing effects of co-stimulation blockade rest on functional dominance of CD4+CD25+ regulatory T cells. Transplantation. 2005;79:147-156.
55. Liang S, Alard P, Zhao Y, et al. Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus. J Exp Med. 2005;201:127-137.